All In Biotech

Drug Trial Radar · NCT04046445

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Jan 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Jul 22, 2019

Primary completion

May 31, 2025

Study completion Aug 31, 2025

Sponsor

Lead sponsor
Amal TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Boehringer Ingelheim
First posted
Aug 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, non-randomised Phase 1b study to evaluate the safety and tolerability of ATP128 alone or in combination with BI 754091 and of heterologous prime-boost ATP128 + VSV-GP128 in combination with BI 754091. ATP128 is a self-adjuvanted chimeric recombinant protein vaccine being developed in combination with programmed cell death 1 (PD-1) blockade for the treatment of microsatellite stable (MSS) patients not responding to PD-1 blockade. The PD-1 inhibitor being tested with ATP128 is the BI 754091 (Ezabenlimab) compound which belongs to the human immunoglobulin G4 (IgG4) subclass of antibodies. VSV-GP is a recombinant chimeric vesicular stomatitis virus (VSV, Indiana strain Rhabdoviridae) which carries the envelope glycoprotein (GP) of the visceral non neurotropic WE-HPI strain of the Lymphocytic choriomeningitis virus (LCMV, Arenaviridae) instead of the native VSV glycoprotein (G) and is developed as integral part of the prime-boost regimen together with ATP128. The Sponsor plans to enrol 96 patients with histologically or cytologically confirmed stage IV colorectal cancer coming form three different patient populations: * Cohort 1a: 6 patients with stage IV colorectal cancer (CRC) having failed standard of care (SoC) therapies * Cohorts 1b, 2a, 2c: 30 patients with stage IV microsatellite stable/mismatch repair-proficient (MSS/MMRp) CRC being in stable disease (SD) or partial response (PR) after first line of SoC (4-6 months duration at minimum) * Cohorts 2b, 4b: 30 patients with stage IV MSS/MMRp liver-limited disease Patients eligible for this study will be enrolled in one of the 8 cohorts depending on their disease: * Patients in Cohort 1a will receive ATP128 as single agent * Patients in Cohorts 1b, 2a, 2b, 2c will receive ATP128 in combination with BI 754091 * Patients in Cohorts 3, 4a, 4b will receive ATP128 and VSV-GP128 in combination with BI 754091

Conditions

  • Colorectal Cancer
  • MSS
  • Stage IV Colon Cancer
  • Stage IV Rectal Cancer
  • Metastatic Colorectal Cancer
  • Liver Metastasis Colon Cancer

Interventions

  • ATP128Drug

    5-6 SC injections

  • BI 754091Drug

    ≥ 7 IV infusions

  • VSV-GP128Drug

    1 single IV injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate safety and tolerability by measure of incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0Time frame: 1 year
  2. valuate anti-tumor effect of study treatment by measure of Progression-free survival (PFS)Time frame: 6 months

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • Honor Health Institute

    Scottsdale, Arizona

  • University of Southern California

    Los Angeles, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • NYU Langone Health

    New York, New York

  • Weill Cornell Medicine

    New York, New York

  • Duke Cancer Institute

    Durham, North Carolina

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas

  • University Hospital Antwerpen

    Edegem, Belgium

  • University Hospital Leuven

    Leuven, Belgium

  • University Medicine Mainz

    Mainz, Germany

  • Geneva University Hospitals

    Geneva, Switzerland

  • University Hospital Zurich

    Zurich, Canton of Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.